Yan Dongmei, Zhao Hongyi, Li Chenxi, Xia Aiting, Zhang Jiaojiao, Zhang Si, Yun Qing, Li Xiaoxin, Huang Feng, Tian Yan
General Hospital of Air Force, PLA, Beijing, China.
Plastic Surgery of Beijing Hospital, National Center for Geriatrics, Chinese Academy of Medical Sciences Institute of Geriatrics, Beijing, China.
Photodermatol Photoimmunol Photomed. 2022 Jan;38(1):53-59. doi: 10.1111/phpp.12716. Epub 2021 Jul 17.
To study the clinical efficacy, recurrence rate and safety of 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) combined with microneedle or CO2 lattice laser (CO2FL), in comparison with intrascar betamethasone injection in the treatment of hypertrophic acne scar.
Fifty-two patients with hypertrophic acne scars at the mandibular angle were enrolled and assigned to different therapy groups. Sixteen patients were treated with microneedle-assisted incorporation of ALA. Twenty-eight patients underwent CO2FL-assisted incorporation of ALA. Eight patients received standard therapy with intrascar injection of glucocorticoid. Two dermatologists, blinded to the therapy groups, independently evaluated the scars in all patients using the average value of the Vancouver Scar Scale score, which was treated as an integer variable.
After three rounds of treatment, there was no significant difference in therapeutic effective rate among the microneedle, laser and topical glucocorticoid groups (93.75% vs 100% vs 100%, P = .855). One out of 16 patients (6.25%) in the microneedle group, no patient (0%) in the laser group and two out of eight patients (25%) in the topical glucocorticoid group had recurrence. The laser group showed a higher rate of adverse effects, which were usually mild and reversible, except for pigmentation. Adverse reactions could be completely subsided within 3 weeks.
Either CO2FL or microneedle combined ALA-PDT for hypertrophic scar, as to topical glucocorticoid therapy, showed equivalent clinical effects but lower recurrence rate within 6 months of follow-up period.
研究基于5-氨基酮戊酸的光动力疗法(ALA-PDT)联合微针或二氧化碳点阵激光(CO2FL)治疗增生性痤疮瘢痕的临床疗效、复发率及安全性,并与瘢痕内注射倍他米松进行比较。
纳入52例下颌角增生性痤疮瘢痕患者,分为不同治疗组。16例患者接受微针辅助ALA导入治疗。28例患者接受CO2FL辅助ALA导入治疗。8例患者接受糖皮质激素瘢痕内注射的标准治疗。两名对治疗组不知情的皮肤科医生,使用温哥华瘢痕量表评分的平均值作为整数变量,对所有患者的瘢痕进行独立评估。
经过三轮治疗,微针组、激光组和局部糖皮质激素组的治疗有效率无显著差异(93.75%对100%对100%,P = 0.855)。微针组16例患者中有1例(6.25%)复发,激光组无患者(0%)复发,局部糖皮质激素组8例患者中有2例(25%)复发。激光组不良反应发生率较高,除色素沉着外,通常为轻度且可逆。不良反应可在3周内完全消退。
对于增生性瘢痕,CO2FL或微针联合ALA-PDT与局部糖皮质激素治疗相比,临床效果相当,但在随访6个月内复发率较低。